Regular Article
Genetic and Clinical Description of Hemochromatosis Probands and Heterozygotes: Evidence That Multiple Genes Linked to the Major Histocompatibility Complex Are Responsible for Hemochromatosis,☆☆

https://doi.org/10.1006/bcmd.1997.0129Get rights and content

Abstract

ABSTRACT: We evaluated Alabama hemochromatosis probands (n= 74) and normal control subjects (n= 142) for expression of the hemochromatosis-associated mutations nt 845G→A (845A; Cys282Tyr) and nt 187C→G (His63Asp) in a gene linked to the major histocompatibility complex (MHC). We also tabulated parameters of iron metabolism and iron overload in probands and in obligate heterozygote family members of homozygous Cys282Tyr probands. Among probands, 59.4% were Cys282Tyr homozygotes and 20.3% were heterozygotes; 20.3% did not express this mutation. In normal control subjects, 14.7% were heterozygous for the Cys282Tyr mutation; one normal control subject was homozygous for the Cys282Tyr mutation. None (0 of 44) of our Cys282Tyr-homozygous hemochromatosis probands had the His63Asp mutation. Of the Cys282Tyr-heterozygous and -negative probands, the His63Asp mutation occurred in 26.7% (4/15) and 53.3% (8/15), respectively. In normal control subjects, 23.2% were heterozygous for the His63Asp mutation; 2.8% were homozygous. Induction phlebotomy requirements and other manifestations of iron overload were significantly greater in Cys282Tyr homozygotes than among other probands. Cys282Tyr-heterozygous probands had significantly higher values of serum iron parameters than did obligate Cys282Tyr heterozygotes whose values were, on the average, normal. Co-expression of HLA-A3, HLA-B7, and D6S105(8) was significantly more frequent in all subgroups of probands stratified by Cys282Tyr expression than in normal control subjects. These results demonstrate that the severity of iron overload in hemochromatosis is affected significantly by genetic factors. Further, our findings support the hypothesis that one or more MHC-linked genes other than that corresponding to the Cys282Tyr and His63Asp mutations contributes to increased iron absorption and iron overload in hemochromatosis probands.

References (41)

  • R Moirand et al.

    A new syndrome of liver iron overload with normal transferrin saturation

    Lancet

    (1997)
  • CQ Edwards et al.

    Prevalence of hemochromatosis among 11,065 presumably healthy blood donors

    N Engl J Med

    (1988)
  • M Simon et al.

    Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis

    Gut

    (1976)
  • M Simon et al.

    Genetics of hemochromatosis: HLA association and mode of inheritance

    Ann N Y Acad Sci

    (1988)
  • EC Jazwinska et al.

    Localization of the hemochromatosis gene close to D6S105

    Am J Hum Genet

    (1993)
  • D HG Crawford et al.

    Evidence that the ancestral haplotype in Australian hemochromatosis patients may be associated with a common mutation in the gene

    Am J Hum Genet

    (1995)
  • JN Feder et al.

    A novel MHC class-I-like gene is mutated in patients with hereditary hemochromatosis

    Nat Genet

    (1996)
  • JC Barton et al.

    Normal transferrin saturation in hemochromatosis

    Hosp Pract

    (1991)
  • RW Chapman et al.

    Hepatic iron stores and markers of iron overload in alcoholics and patients with idiopathic hemochromatosis

    Dig Dis Sci

    (1982)
  • MJ Pippard

    Secondary iron overload in iron metabolism in health and disease

    Iron Metabolism in Health and Disease

    (1994)
  • Cited by (155)

    • HFE hemochromatosis in African Americans: Prevalence estimates of iron overload and iron overload-related disease

      2023, American Journal of the Medical Sciences
      Citation Excerpt :

      We found no description of an AA with HFE p.H63D/p.H63D identified either in population screening or in a referral evaluation who had documented IO as defined herein. Proportions of referred EA and European patients in hemochromatosis case series with p.H63D/p.H63D are very low.3,20-23 The proportion of referred patients with p.H63D/p.H63D who have documented IO is also very low.21-23

    • Iron Metabolism and Related Disorders

      2013, Emery and Rimoin's Principles and Practice of Medical Genetics
    • Increased Risk of Death From Iron Overload Among 422 Treated Probands With HFE Hemochromatosis and Serum Levels of Ferritin Greater Than 1000 μg/L at Diagnosis

      2012, Clinical Gastroenterology and Hepatology
      Citation Excerpt :

      We included probands who (1) were diagnosed to have hemochromatosis during medical care; (2) had HFE C282Y homozygosity; (3) were treated to achieve iron depletion by phlebotomy if SF levels at diagnosis were elevated (men, >300 μg/L; women, >200 μg/L)3,14; and (4) resided in central Alabama or Ontario. Each proband was evaluated for complications associated with iron overload, as appropriate.15–17 SF levels were measured using automated clinical methods.

    • Hemochromatosis Genotypes and Risk of Iron Overload-A Meta-Analysis

      2011, Annals of Epidemiology
      Citation Excerpt :

      One article provided separate tabular data for subjects with elevated TS, SF, and sFe, and for those with elevated TS, SF, sFe, HII, HIS, and mobilizable iron by quantitative phlebotomy, thus adding another two studies to the analyses (20). Each of the other articles corresponded to one study, thus cases were selected according to: elevated TS, one study (21); elevated SF, four studies (22–25); elevated TS, SF, and sFe, five studies (26–30); elevated TS, SF sFe, HII, HIS, and mobilizable iron by quantitative phlebotomy, 20 studies (8, 31–49); and elevated HIS and mobilizable iron by quantitative phlebotomy, five studies (50–54). Twelve studies used TS cutoff values of 45%–50%, as follows: overall TS greater than 45% (21, 30, 31, 36, 38), overall TS greater than 50% (8, 32, 37, 44, 48), TS greater than 50% in males and TS greater than 45% in females (20).

    View all citing articles on Scopus

    04/23/97

    ☆☆

    J, H, BrockJ, W, HallidayM, J, PippardL, W, Powell, eds.

    f1

    Reprint request to: Dr. James C. Barton, Southern Iron Disorders Center, Suite G-105, 2022 Brookwood Medical Center Drive, Birmingham AL 35209, phone (205) 877-2888, fax (205) 877-2039, e-mail: [email protected]

    View full text